Summary & Overview
HCPCS Level II S0187: Tamoxifen Citrate, Oral, 10 mg
HCPCS Level II code S0187 denotes tamoxifen citrate, oral, 10 mg — a commonly used endocrine therapy in oncology for hormone receptor–positive cancers. Nationally, this code is used for billing the specific oral medication formulation and dosage, supporting consistent pharmacy and outpatient clinic reimbursement for tamoxifen maintenance and adjuvant therapy. Accurate coding of oral oncology agents is important for claims processing, benefit coordination, and patient cost-sharing calculations across commercial and public payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how S0187 is categorized in claims, common sites of service where it is billed, and typical clinical contexts for tamoxifen use. The publication summarizes benchmarks and policy-relevant considerations affecting coverage and billing for oral oncologic agents, highlights where coding precision matters for pharmacy versus medical benefit adjudication, and outlines implications for reimbursement workflows.
Data not available in the input is noted where specific payer policies, associated taxonomies, ICD-10 pairings, and related codes are required for detailed billing guidance.
Billing Code Overview
HCPCS Level II code S0187 represents Tamoxifen citrate, oral, 10 mg. This code denotes the drug formulation and dosage for oral tamoxifen therapy.
-
Service type: Pharmacy-dispensed oral anticancer endocrine therapy
-
Typical site of service: Outpatient pharmacy or outpatient clinic / physician office dispensing
Clinical & Coding Specifications
Clinical Context
Patient is a 52-year-old woman with estrogen receptor–positive early-stage breast cancer who is prescribed oral endocrine therapy with tamoxifen citrate S0187 (tamoxifen citrate, oral, 10 mg) for adjuvant treatment and recurrence risk reduction. Initiation typically occurs in the outpatient oncology clinic following surgical treatment (lumpectomy or mastectomy) and completion of any indicated chemotherapy or radiation. The clinical workflow includes: medication counseling and informed consent by the oncologist or advanced practice provider; baseline assessment of menopausal symptoms, history of thromboembolic events, and liver function tests; prescription processing through the oncology infusion pharmacy or specialty pharmacy; administration of the drug as an outpatient oral prescription with routine follow-up visits at 3-month, 6-month, and annual intervals to monitor efficacy, adherence, side effects (hot flashes, vaginal symptoms), and safety labs. Pharmacy billing uses HCPCS Level II code S0187 for billed tamoxifen supplies when applicable to payor reimbursement policies. Typical documentation includes diagnosis linking (breast cancer ICD-10), start date, dose (10 mg tablet), quantity dispensed, directions for use, and any applicable modifier for billing claim adjustments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |